150 related articles for article (PubMed ID: 1560148)
1. The economic implications of bioengineered mastitis control.
Miles H; Lesser W; Sears P
J Dairy Sci; 1992 Feb; 75(2):596-605. PubMed ID: 1560148
[TBL] [Abstract][Full Text] [Related]
2. Use of partial budgeting to determine the economic outcome of Staphylococcus aureus intramammary infection reduction strategies in three Ohio dairy herds.
Hoblet KH; Miller GY
J Am Vet Med Assoc; 1991 Sep; 199(6):714-20. PubMed ID: 1955362
[TBL] [Abstract][Full Text] [Related]
3. Vaccines against bovine mastitis in the New Zealand context: what is the best way forward?
Denis M; Wedlock DN; Lacy-Hulbert SJ; Hillerton JE; Buddle BM
N Z Vet J; 2009 Jun; 57(3):132-40. PubMed ID: 19521461
[TBL] [Abstract][Full Text] [Related]
4. Benefits and costs of a control program for an epizootic of Staphylococcus aureus mastitis.
Goodger WJ; Ferguson G
J Am Vet Med Assoc; 1987 May; 190(10):1284-7. PubMed ID: 3108206
[TBL] [Abstract][Full Text] [Related]
5. Protection against Staphylococcus aureus mastitis in dairy cows using a bismuth-based teat seal containing the bacteriocin, lacticin 3147.
Twomey DP; Wheelock AI; Flynn J; Meaney WJ; Hill C; Ross RP
J Dairy Sci; 2000 Sep; 83(9):1981-8. PubMed ID: 11003227
[TBL] [Abstract][Full Text] [Related]
6. Cow-specific treatment of clinical mastitis: an economic approach.
Steeneveld W; van Werven T; Barkema HW; Hogeveen H
J Dairy Sci; 2011 Jan; 94(1):174-88. PubMed ID: 21183029
[TBL] [Abstract][Full Text] [Related]
7. Immunological responses and evaluation of the protection in dairy cows vaccinated with staphylococcal surface proteins.
Merrill C; Ensermu DB; Abdi RD; Gillespie BE; Vaughn J; Headrick SI; Hash K; Walker TB; Stone E; Kerro Dego O
Vet Immunol Immunopathol; 2019 Aug; 214():109890. PubMed ID: 31378218
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of vaccination and antimicrobial treatment to eliminate chronic intramammary Staphylococcus aureus infections in dairy cattle.
Smith GW; Lyman RL; Anderson KL
J Am Vet Med Assoc; 2006 Feb; 228(3):422-5. PubMed ID: 16448371
[TBL] [Abstract][Full Text] [Related]
9. Bioeconomic modeling of intervention against clinical mastitis caused by contagious pathogens.
Halasa T
J Dairy Sci; 2012 Oct; 95(10):5740-9. PubMed ID: 22863098
[TBL] [Abstract][Full Text] [Related]
10. Economic losses from and the national research program on mastitis in the United States.
Blosser TH
J Dairy Sci; 1979 Jan; 62(1):119-27. PubMed ID: 379057
[TBL] [Abstract][Full Text] [Related]
11. Estimate of the economic impact of mastitis: A case study in a Holstein dairy herd under tropical conditions.
Guimarães JLB; Brito MAVP; Lange CC; Silva MR; Ribeiro JB; Mendonça LC; Mendonça JFM; Souza GN
Prev Vet Med; 2017 Jul; 142():46-50. PubMed ID: 28606365
[TBL] [Abstract][Full Text] [Related]
12. Severity of E. coli mastitis is mainly determined by cow factors.
Burvenich C; Van Merris V; Mehrzad J; Diez-Fraile A; Duchateau L
Vet Res; 2003; 34(5):521-64. PubMed ID: 14556694
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle.
Chang BS; Moon JS; Kang HM; Kim YI; Lee HK; Kim JD; Lee BS; Koo HC; Park YH
Vaccine; 2008 Apr; 26(17):2081-91. PubMed ID: 18387721
[TBL] [Abstract][Full Text] [Related]
14. Field trials of a vaccine against bovine mastitis. 2. Evaluation in two commercial dairy herds.
Calzolari A; Giraudo JA; Rampone H; Odierno L; Giraudo AT; Frigerio C; Bettera S; Raspanti C; Hernández J; Wehbe M; Mattea M; Ferrari M; Larriestra A; Nagel R
J Dairy Sci; 1997 May; 80(5):854-8. PubMed ID: 9178125
[TBL] [Abstract][Full Text] [Related]
15. Production effects related to mastitis and mastitis economics in dairy cattle herds.
Seegers H; Fourichon C; Beaudeau F
Vet Res; 2003; 34(5):475-91. PubMed ID: 14556691
[TBL] [Abstract][Full Text] [Related]
16. Partial budget of the discounted annual benefit of mastitis control strategies.
Allore HG; Erb HN
J Dairy Sci; 1998 Aug; 81(8):2280-92. PubMed ID: 9749395
[TBL] [Abstract][Full Text] [Related]
17. A partial budget model to estimate economic benefits of lactational treatment of subclinical Staphylococcus aureus mastitis.
Swinkels JM; Hogeveen H; Zadoks RN
J Dairy Sci; 2005 Dec; 88(12):4273-87. PubMed ID: 16291618
[TBL] [Abstract][Full Text] [Related]
18. Costs of mastitis: facts and perception.
Huijps K; Lam TJ; Hogeveen H
J Dairy Res; 2008 Feb; 75(1):113-20. PubMed ID: 18226298
[TBL] [Abstract][Full Text] [Related]
19. Partial budget analysis of vaccinating dairy cattle against coliform mastitis with an Escherichia coli J5 vaccine.
DeGraves FJ; Fetrow J
J Am Vet Med Assoc; 1991 Aug; 199(4):451-5. PubMed ID: 1917656
[TBL] [Abstract][Full Text] [Related]
20. Staphylococcus aureus antigens and challenges in vaccine development.
Middleton JR
Expert Rev Vaccines; 2008 Aug; 7(6):805-15. PubMed ID: 18665778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
